Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis
Authors' conclusion
Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT.
Study context
- Population
- Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)
- Participants
- 35,326 patients · 15 randomized clinical trials (RCTs)
- Comparison
- Short-term DAPT strategies vs 12 months of DAPT
- Outcome
- Efficacy: MACCE; safety: major bleeding
Methodological detailsbayesian random-effects, surface under the cumulative ranking (SUCRA) ranking
- Bayesian random-effects
- SUCRA ranking
Pooled result
As reported in the abstract
Each group vs 12 months of DAPTRelative risk (95% CrI)
1 month of DAPT followed by P2Y12 inhibitorsmajor bleeding; CrI
0.47(0.26–0.74)
1 month of DAPT followed by P2Y12 inhibitorsMACCE; CrI
1.00(0.70–1.41)
3 months of DAPT followed by P2Y12 inhibitorsMACCE; CrI; ranked optimal by SUCRA
0.85(0.56–1.21)
Original publication
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. JAMA Cardiol. Published 1 December 2024. doi:10.
Summarised from the published abstract; every number is checked against it